Secular Trends of Intrahepatic Cholangiocarcinoma in a High Endemic Area: A Population-based Study

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Sep 26

PMID 36161044

Authors

Chun-Ru Lin

Yu-Kwang Lee

Chun-Ju Chiang

Ya-Wen Yang

Hung-Chuen Chang

San-Lin You

Affiliations

Soon will be listed here.

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is one of the most aggressive malignancies. However, because of its scarcity there are limited population-based data available for investigations into its epidemiologic characteristics. In Taiwan, we have a national cancer registry database that can be used to evaluate the secular trends of ICC.

Aim: To evaluate secular trends of ICC according to age, sex, and risk factors in Taiwan.

Methods: In this population-based study, we used the national Taiwan Cancer Registry database. Age-standardized and relative percent changes in incidence rates were used to describe secular trends in incidence rates and sex ratios of ICC in Taiwan.

Results: The age-standardized ICC incidence rate among males increased from 1.51 per 100000 in 1993-1997 to 4.07 per 100000 in 2013-2017 and among female from 1.73 per 100000 to 2.95 per 100000. The incidence in females tended to plateau after 2008-2012. For males, the ICC incidence increased as age increased. In the long-term incidence trend of ICC in females, the incidence of the four age groups (40-44, 45-49, 50-54 and 55-59 years) remained stable in different years; although, the incidence of the 60-64 group had a peak in 2003-2007, and the peak incidence of the 65-69 and 70-74 groups occurred in 2008-2012. Among males, beginning at the age of 65, there were increases in the incidence of ICC for the period of 2003-2017 as compared with females in the period of 2003-2017.

Conclusion: Increased incidence of ICC occurred in Taiwan over the past two decades. The increased incidence has progressively shifted toward younger people for both males and females.

Citing Articles

To accurately predict lymph node metastasis in patients with mass-forming intrahepatic cholangiocarcinoma by using CT radiomics features of tumor habitat subregions.

Chen P, Yang Z, Ning P, Yuan H, Qi Z, Li Q Cancer Imaging. 2025; 25(1):19.

PMID: 40011960 PMC: 11863903. DOI: 10.1186/s40644-025-00842-8.

Spatial analysis of cholangiocarcinoma in Thailand from 2012 to 2021; a population-based cancer registries study.

Sahat O, Kamsa-Ard S, Suwannatrai A, Lim A, Kamsa-Ard S, Bilheem S PLoS One. 2024; 19(12):e0311035.

PMID: 39661606 PMC: 11633966. DOI: 10.1371/journal.pone.0311035.

Outcomes of liver resection in hepatitis C virus-related intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.

Cheo F, Chan K, Shelat V World J Virol. 2024; 13(1):88946.

PMID: 38616852 PMC: 11008402. DOI: 10.5501/wjv.v13.i1.88946.

Locoregional Therapy for Intrahepatic Cholangiocarcinoma: The Role of Intra-Arterial Therapies.

Gorji L, Aoun H, Critchfield J, Al Hallak N, Beal E Cancers (Basel). 2023; 15(19).

PMID: 37835420 PMC: 10571998. DOI: 10.3390/cancers15194727.

References

Singsuksawat E, Thuwajit C, Charngkaew K, Thuwajit P . Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells. Cancer Cell Int. 2018; 18:25. PMC: 5819217. DOI: 10.1186/s12935-018-0525-z. View

Jing W, Jin G, Zhou X, Zhou Y, Zhang Y, Shao C . Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev. 2011; 21(1):24-31. DOI: 10.1097/CEJ.0b013e3283481d89. View

Navas M, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F . Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. Am J Pathol. 2019; 189(6):1122-1132. DOI: 10.1016/j.ajpath.2019.01.018. View

Chiang K, Yeh C, Lin K, Su L, Yen T, Pang J . Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model. Oncotarget. 2014; 5(11):3849-61. PMC: 4116525. DOI: 10.18632/oncotarget.2000. View

Tsao Y, Chen J, Yeh W, Peng Y, Li W . Association between visceral obesity and hepatitis C infection stratified by gender: a cross-sectional study in Taiwan. BMJ Open. 2017; 7(11):e017117. PMC: 5695385. DOI: 10.1136/bmjopen-2017-017117. View

Kreng V, Yang C . The equality of resource allocation in health care under the National Health Insurance System in Taiwan. Health Policy. 2010; 100(2-3):203-10. DOI: 10.1016/j.healthpol.2010.08.003. View

Chiang C, You S, Chen C, Yang Y, Lo W, Lai M . Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015; 45(3):291-6. DOI: 10.1093/jjco/hyu211. View

Lin C, Li C, Hsiao C, Liu C, Yang S, Lee C . Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study. BMC Public Health. 2013; 13:318. PMC: 3626657. DOI: 10.1186/1471-2458-13-318. View

Jiang W, Li F, Yang H, Chen G, Hua Y . Relationship Between Fish Oil Use and Incidence of Primary Liver Cancer: Findings From a Population-Based Prospective Cohort Study. Front Nutr. 2022; 8:771984. PMC: 8759152. DOI: 10.3389/fnut.2021.771984. View

10.

Antwi S, Patel T . Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?. Hepatobiliary Surg Nutr. 2020; 8(6):635-636. PMC: 6943003. DOI: 10.21037/hbsn.2019.10.10. View

11.

Mosadeghi S, Liu B, Bhuket T, Wong R . Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. Hepatol Res. 2015; 46(7):669-77. DOI: 10.1111/hepr.12605. View

12.

Dodson R, Weiss M, Cosgrove D, Herman J, Kamel I, Anders R . Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013; 217(4):736-750.e4. DOI: 10.1016/j.jamcollsurg.2013.05.021. View

13.

Alvaro D, Crocetti E, Ferretti S, Bragazzi M, Capocaccia R . Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2009; 42(7):490-5. DOI: 10.1016/j.dld.2009.10.009. View

14.

Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag H . Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019; 71(1):104-114. DOI: 10.1016/j.jhep.2019.03.013. View

15.

Saha S, Zhu A, Fuchs C, Brooks G . Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016; 21(5):594-9. PMC: 4861366. DOI: 10.1634/theoncologist.2015-0446. View

16.

Wen C, Levy D, Cheng T, Hsu C, Tsai S . Smoking behaviour in Taiwan, 2001. Tob Control. 2005; 14 Suppl 1:i51-5. PMC: 1766183. DOI: 10.1136/tc.2004.008011. View

17.

Chiang C, Wang Y, Lee W . Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future. J Formos Med Assoc. 2019; 118(5):856-858. DOI: 10.1016/j.jfma.2019.01.012. View

18.

Wen C, Tsai S, Chen C, Cheng T, Tsai M, Levy D . Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. Tob Control. 2005; 14 Suppl 1:i76-80. PMC: 1766186. DOI: 10.1136/tc.2004.007955. View

19.

Matsumoto K, Onoyama T, Kawata S, Takeda Y, Harada K, Ikebuchi Y . Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med. 2014; 53(7):651-4. DOI: 10.2169/internalmedicine.53.1410. View

20.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View